Palo Alto, CA, United States of America

Trini Arroyo


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Trini Arroyo: Innovator in Liver Cancer Research

Introduction

Trini Arroyo is a notable inventor based in Palo Alto, California. He has made significant contributions to the field of cancer research, particularly in the development of targeted therapies for liver cancer. His innovative work focuses on the use of specific promoter sequences to enhance the effectiveness of adenoviral vectors in treating hepatocellular carcinoma.

Latest Patents

Trini Arroyo holds a patent for a "Hepatocellular carcinoma specific promoter and uses thereof." This patent addresses liver cancer by providing specific promoter sequences and adenovirus vehicles. The technology allows for transcriptional regulation that is dependent on transcription factors active only in certain cell types. This targeted approach restricts virus replication to the intended cells, enhancing the therapeutic potential of the modified adenovirus. The invention may introduce new genetic capabilities associated with cytotoxicity for treating neoplasia.

Career Highlights

Trini Arroyo is currently employed at Cell Genesys, Inc., where he continues to advance his research in cancer therapies. His work has been instrumental in developing innovative solutions for complex medical challenges. With a focus on hepatocellular carcinoma, Arroyo's contributions are paving the way for more effective treatments.

Collaborations

Trini Arroyo collaborates with Yuanhao Li, who is also involved in cancer research. Their partnership exemplifies the importance of teamwork in scientific innovation and the pursuit of groundbreaking solutions in medicine.

Conclusion

Trini Arroyo's work in liver cancer research highlights the potential of targeted therapies in oncology. His innovative patent and ongoing contributions to Cell Genesys, Inc. reflect his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…